Clinical Trial Update: Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2) [Phase 3]

View source ↗

Summary

Phase 3 STARTverso 2 trial evaluated faldaprevir in combination with pegylated interferon-alfa and ribavirin for treatment-naïve genotype 1 hepatitis C patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Faldaprevir (faldaprevir)
• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2015-09-18